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ABSTRACT 46 
Background: Maternal supplementation with long chain n-3 polyunsaturated fatty acids (PUFAs) 47 
may have immunological effects on the developing fetus through several anti-inflammatory 48 
pathways. However, there is limited knowledge of the long-term programming effects. 49 
Objective: In a randomized controlled trial (RCT) from 1990 with 24 years of follow-up, our aim 50 
was to determine if supplementation with 2.7 g long chain n-3 PUFAs in pregnancy can reduce the 51 
risk of offspring asthma and allergic rhinitis. 52 
Methods: The RCT included 533 women who were randomly assigned to receive fish oil during 53 
the 3rd trimester of pregnancy, olive oil, or no oil in the ratio 2:1:1. The offspring were followed in a 54 
mandatory national prescription register with complete follow-up for prescriptions related to the 55 
treatment of asthma and allergic rhinitis as primary outcomes. The offspring were furthermore 56 
invited to complete a questionnaire (74% participated) and to attend a clinical examination (47% 57 
participated) at age 18-19 years.  58 
Results: In intention-to-treat analyses, the probability of having had asthma medication prescribed 59 
was significantly reduced in the fish oil group compared to the olive oil group (HR=0.54, 95% 60 
CI:0.32-0.90, p=0.02). The probability of having had allergic rhinitis medication prescribed was 61 
also reduced in the fish oil group compared to the olive oil group (HR=0.70, 95% CI:0.47-1.05, 62 
p=0.09), but the difference was not statistically significant. Self-reported information collected at 63 
age 18-19 years supported these findings. No effects were seen on lung function or allergic 64 
sensitization at 18-19 years of age. 65 
Conclusion: Maternal supplementation with fish oil may have prophylactic potential for long-term 66 
prevention of offspring asthma. 67 
  68 
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Key messages 69 
• In this randomized controlled trial with 24-years of follow-up, maternal supplementation 70 
with fish oil reduced the risk of asthma medication use in the offspring compared to a 71 
placebo group that received olive oil.  72 
• Maternal supplementation with fish oil was, however, not associated with allergic 73 
sensitization or lung function at 18 years of age. 74 
• This advocates for a potential role of long chain n-3 PUFAs in preventing offspring asthma 75 
in a long term perspective.  76 
 77 
Capsule summary 78 
Results from this randomized controlled trial with 24 years of follow-up support the hypothesis that 79 
supplementation with long chain n-3 polyunsaturated fatty acids in pregnancy may have 80 
prophylactic potential for preventing offspring asthma.  81 
 82 
Key words 83 
Randomized controlled trial, fetal programming, asthma, allergies, n-3 polyunsaturated fatty acids 84 
 85 
Abbreviations 86 
ATC: Anatomical Therapeutic Chemical classification system 87 
BMI: body mass index 88 
CI: confidence interval 89 
DHA: docosahexaenoic acid 90 
DNPR: Danish National Patient Registry 91 
ECP: eosinophil cationic protein 92 
EPA: eicosapentaenoic acid 93 
FEV1: forced expiratory volume in the first second 94 
FVC: forced vital capacity 95 
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HR: hazard ratio 96 
ICD: International Classification of Diseases 97 
IgE: immunoglobulin E 98 
IQR: interquartile range 99 
OR: odds ratio 100 
PUFA: polyunsaturated fatty acids 101 
RCT: randomized controlled trial 102 
RMPS: Register of Medicinal Product Statistics  103 
SD: standard deviation 104 
 105 
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INTRODUCTION 108 
There is increasing evidence that environmental factors in fetal life may impact the individual’s 109 
susceptibility to develop asthma and allergic diseases.1 Particular focus has been on maternal intake 110 
of the long chain n-3 polyunsaturated fatty acids (LCn3PUFAs), eicosapentaenoic acid (EPA, 111 
20:5n-3), and docosahexaenoic acid (DHA, 22:6n-3), abundant in seafood and fish oil. EPA and 112 
DHA may affect the function of the fetal immune system through several anti-inflammatory 113 
mechanisms resulting in a reduced TH2 allergic immune response.2 This has been substantiated in 114 
two previous randomised controlled trials (RCTs) with fish oil supplementation leading to reduced 115 
formation of cytokines produced by TH2 cells at birth.3-5 Fish oil supplementation furthermore had a 116 
beneficial effect on skin sensitization and immunoglobulin E (IgE) related food reactions and 117 
eczema in infants up to 12 months.6 In 2008, Olsen et al. published results from the first randomised 118 
placebo controlled trial that investigated the long-term effect of fish oil supplementation in late 119 
pregnancy and they reported a beneficial effect on offspring asthma discharge diagnoses from a 120 
mandatory national patient register.7 However, since only patients seen in hospitals are reported to 121 
the patient register8, asthma discharge diagnoses from this register are known to underestimate the 122 
true occurrence of asthma in the general population.9  123 
 124 
In the same RCT, we therefore decided to extend the analyses with methods of asthma and allergic 125 
rhinitis ascertainment that are more relevant for the general population, and with follow-up up until 126 
24 years of age. Our aim was to determine whether our previously reported reduced occurrence of 127 
asthma discharge diagnoses in offspring whose mother had taken fish oil in pregnancy could be 128 
extended to a more varied phenotype that also included mild and moderate manifestations of 129 
allergic respiratory disease and may be more important for disease prevention on a population level. 130 
131 
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METHODS 132 
Study cohort  133 
The Aarhus Trial recruited 533 Danish pregnant women (61% of those eligible) with singleton 134 
pregnancies through antenatal care clinics in 1990. The women were block-randomised in the ratio 135 
2:1:1 stratified by parity to three groups that received a daily supplementation of either fish oil, 136 
olive oil, or no oil from gestational week 30 until delivery. The study design and the original aim 137 
have been described in detail elsewhere.10 Briefly, 266 women were randomised to the intervention 138 
group and received four 1g gelatine capsules with fish oil (Pikasol®: 32% EPA, 23% DHA and 2 139 
mg tocopherol/ml)) daily, corresponding to 2.7 g LCn3PUFAs per day. An additional 136 women 140 
were randomised to the placebo group and were given four similar looking 1 g capsules with olive 141 
oil (72 % oleic acid (18:1n-9) and 12 % linoleic acid (18:2n-6)) per day. Women allocated to the 142 
two oil capsule groups and the study coordinators were blinded to treatment allocation. A third 143 
group of 131 women were randomised to receive no oil capsules but were informed about the 144 
purpose of the trial and about the potential beneficial effects of supplementation with n-3 fatty 145 
acids, thus acting as a passive intervention positive control. Active fish oil supplementation was 146 
associated with longer gestations10 when compared against placebo, and it raised maternal EPA-147 
derived thromboxane and prostacyclin production11, and increased the concentrations of long chain 148 
n-3 PUFAs in umbilical blood and tissues12 and in the early breast milk13 when compared against a 149 
combination of both control groups.   150 
 151 
In 2008-2009, a follow-up of the 18-19-year old offspring of originally enrolled mothers was 152 
undertaken. At that time, 517 (97%) mother-child dyads were still alive and living in Denmark. An 153 
overview of the original trial and the follow-up is presented in Figure 1.  154 
 155 
The study was approved by the local ethics committee (M-ÅA 20060182) and the Danish Data 156 
Protection Agency (journal no. 2006-41-6257), and all participants gave written consent. The 157 
Aarhus Trial is registered under NCT01353807. 158 
 159 
Register-based outcomes 160 
We assessed cases of asthma medication use from the national prescription register that holds 161 
information on all prescriptions filled in Danish pharmacies written by doctors from all levels of the 162 
health care sector.14 This allows for complete follow-up for all individuals remaining within the 163 
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country over their lifetime. We were able to follow-up 522 of the 533 individuals born to women in 164 
the trial (98%); the remaining 11 individuals were lost to follow-up due to emigration. We used 165 
Anatomical Therapeutic Chemical classification system (ATC) codes R03A, R03B, R03C, and 166 
R03D for asthma and ATC codes R01AC, R01AD, R01AX, R06A, S01GA, and S01GX for allergic 167 
rhinitis. We defined cases of asthma medication using a modified validated definition15 as those 168 
who had filled ≥ 2 prescriptions for beta-2-agonists or steroids or ≥ 1 prescription for leukotriene 169 
receptor antagonists. Allergic rhinitis cases were defined as those having filled ≥ 2 allergic rhinitis 170 
prescriptions including eye drops, nasal decongestants, and oral anti-histamines. The capture time 171 
was from the start of the register in 1995 until the end of 2014.  172 
 173 
As in our previous report,7 we also identified individuals with a discharge diagnosis of asthma from 174 
the national patient register. Follow-up was extended by 7 years relative to our previous report, 175 
through the end of 2013. Briefly, we used International Classification of Diseases (ICD) 8 and ICD-176 
10 codes 493.00, 493.01, 493.02, 493.08, 493.09, J45.0, J45.1, J45.2, J45.8, J45.9. Hospital 177 
diagnoses of allergic rhinitis were not included as an outcome due to few cases (n=9, 1%).  178 
 179 
Clinical outcomes and biomarkers  180 
We performed lung function testing and obtained blood samples from 243 individuals (46%) who 181 
participated in a follow-up clinical examination at age 18-19 years in 2008-2009. Serum total IgE, 182 
specific IgE against 12 common inhalant allergens, and eosinophil cationic protein (ECP) were 183 
quantified by fluoroimmunoassay using ImmunoCAP (Phadia Laboratory Systems AB, Uppsala 184 
Sweden). ‘Allergic sensitization’ was defined as a positive test for specific IgE (≥0.35 kUA/L) to at 185 
least one of the 12 allergens. A cutoff of ≥1.00 kUA/L was also examined. Based on sensitization 186 
status (≥0.35 kUA/L), we furthermore examined phenotypes of allergic asthma (asthma medication 187 
use with sensitization) and non-allergic asthma (asthma medication use without sensitization). 188 
Forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) were measured 189 
using a daily calibrated Vitalograph spirometer (Vitalograph, Ireland). From these measurements 190 
we calculated the ratio of FEV1/FVC and the FEV1 in % of predicted value (FEV1%predicted) 191 
(based on values from Qaunjer et al.) 16 as continuous variables.  192 
 193 
 194 
 195 
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Self-reported outcomes 196 
In 2008, at ~18 years of age, 382 offspring (72%) completed a self-administered web-based 197 
questionnaire with four questions on asthma and hayfever that followed the International Studies on 198 
Asthma and Allergies in Childhood core questionnaire.17 Based on answers to this questionnaire we 199 
identified individuals reporting ‘Ever doctor diagnosed asthma’, ‘Ever doctor diagnosed hayfever’, 200 
‘Current asthma medication use’, and ‘Current hayfever symptoms’.  201 
 202 
Analytical strategy 203 
We decided a priori to base the evaluation of the effects of fish oil on the comparison between the 204 
fish oil group with the olive oil because these groups consisted of a double blind administration of 205 
oil capsules. Our main analyses therefore included 394 mother-offspring pairs; 260 from the fish oil 206 
group and 134 from the olive oil group. This decision is supported by data collected postpartum and 207 
discussed in detail elsewhere7 showing that the randomization between the two blinded arms 208 
worked well, that olive oil was provided in isocaloric amounts to fish oil, and that the dose of olive 209 
oil could reasonably be assumed to be inert in relation to the outcome under study. In contrast, the 210 
no oil group was unblinded, was informed of the objectives of the study and of the potential health 211 
benefits of fish consumption, and had comparable effects on gestation length to the active 212 
intervention arm in the original trial.10 We therefore considered the no oil arm to represent the effect 213 
of a passive intervention consisting of nutritional advice. Comparisons of outcomes between the no 214 
oil arm and the active intervention (fish oil) and control (olive oil) arms are presented in 215 
Supplementary Tables I-III.  216 
 217 
Cumulative incidence curves were generated using the Kaplan-Meier method. In primary intention-218 
to-treat analyses, Cox proportional hazards regression analysis was used to estimate the effect of 219 
fish oil relative to that of olive oil expressed by hazard ratios (HR) and 95% confidence intervals 220 
(CI); age was used as the underlying time scale. In the national patient register, we followed 221 
offspring from birth in 1990 until first asthma discharge diagnosis, death, or end of follow-up in 222 
2013. In the prescription register, we followed offspring from 1995 when data became available 223 
until first occurrence of medication cases, death, or end of follow-up in 2014. The proportional 224 
hazards assumption was evaluated by visual inspection of residual plots and by a Wald test for 225 
interaction between time and treatment group and was fulfilled in all analyses.  226 
 227 
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In secondary analyses, we used logistic regression models to evaluate the effect of fish oil on self-228 
reported and clinical binary outcomes and calculated odds ratios (OR) and 95% CI. For continuous 229 
outcomes, we used linear regression models to estimate the mean difference or ratios between 230 
geometric means and 95% CIs. Due to the loss to follow-up in these analyses, we could not apply 231 
the intention-to-treat principle, and we therefore decided a priori to adjust for offspring sex and 232 
maternal smoking as recorded in the interview at enrolment in gestational week 30, since these were 233 
the covariates strongest associated with the outcomes in our data. 234 
The following sensitivity analyses were decided upon a priori: stratification by offspring sex, and 235 
adjustment for birth weight and gestational age to investigate if they could explain the potential 236 
impact of fish oil on the outcomes.  237 
 238 
All tests were 2-sided and a p-value of <0.05 was considered to be significant. Analyses were 239 
performed by SAS software package, version 9.3. 240 
  241 
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RESULTS 242 
As reported earlier10, the original randomization worked successfully and created similar trial 243 
groups with respect to the distribution of covariates (data not shown). When we examined the 244 
prevalence of maternal and paternal asthma and hayfever history from the questionnaire completed 245 
by the offspring in 2008, no differences between the trial groups were seen (data not shown). 246 
 247 
Register-based outcomes: The probability of having had asthma medication prescribed was 248 
significantly reduced in the fish oil group compared to the olive oil group (HR=0.54, 95% CI: 0.32-249 
0.90, p=0.02;Table I, Figure 2b). For our analyses based on the patient register we likewise found a 250 
reduced probability of asthma diagnosis in the fish oil vs olive oil group (HR=0.31, 95% CI: 0.13-251 
0.75, p=0.01; Table I, Figure 2a), which is in agreement with our previous evaluation with follow 252 
up until age 16 years. The probability of having had allergic rhinitis medication prescribed was also 253 
reduced in the fish oil group compared to the olive oil group, but this difference was not statistically 254 
significant (HR=0.70, 95% CI: 0.47-1.05, p=0.09; Table I, Figure 2c). Passive intervention had 255 
similar effects to active intervention (supplementary tables I-III). 256 
 257 
Table I.  258 
 259 
 260 
 261 
 262 
 263 
 264 
 265 
 266 
 267 
 268 
Hazard ratios (HRs) and 95% confidence intervals (CI) of register outcomes of asthma and allergic 269 
rhinitis up to 24 years of age in the fish oil group relative to the olive oil group. Hazard ratios 270 
calculated using Cox regression analysis. 271 
 272 
Registry-based outcomes (n=396) N cases (%) Hazard ratios (95% CI) 
Crude 
Asthma discharge diagnosis   
     Fish oil      8 (3%) 0.31 (0.13-0.75) 
     Olive oil 13 (10%) 1.00  
  p=0.01 
Asthma medication    
     Fish oil      31 (12%) 0.54 (0.32-0.90) 
     Olive oil 28 (21%) 1.00 
  p=0.02 
Allergic rhinitis medication    
     Fish oil      57 (22%) 0.70 (0.47-1.05) 
     Olive oil 40 (30%) 1.00 
  p=0.09 
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 273 
 274 
Self-reported outcomes, clinical outcomes, and biomarkers: We observed few differences 275 
between mother-offspring pairs who participated in the follow-up and those who did not (Table II), 276 
but the participation in the clinical examination differed across randomization groups, and was 277 
lower in the fish oil group (44 vs. 55%). In the sample of offspring with self-reported data (Figure 278 
3a, supplementary Table IV), we found lower odds of current asthma medication use (OR=0.34, 279 
95% CI: 0.12-0.99, p=0.049) in the fish oil group compared to the olive oil group after adjustment 280 
for a priori selected confounders. For doctor diagnoses of asthma and hayfever and current hayfever 281 
symptoms, odds were also lower in the fish oil group, but these differences were not statistically 282 
significant. We did not observe any significant differences between the fish oil and the olive oil 283 
groups in lung function measurements, total IgE or specific IgE, or ECP among individuals 284 
presenting to the clinical evaluation (Figure 3b and 3c, supplementary Table IV). Allergic 285 
sensitization with the secondary cutoff of 1.00 KUA/L appeared to be less frequent in the fish oil 286 
group compared to the olive oil group (OR=0.56, 95% CI: 0.28-1.13, p=). When examining asthma 287 
phenotypes, there was a significant effect on allergic asthma (OR=0.27, 95% CI: 0.08-0.93, p=), 288 
whereas there was no significant effect on non-allergic asthma (OR=0.47, 95% CI: 0.16-1.32, p=); 289 
although both estimates were in the same direction. 290 
 291 
Stratification by offspring sex did not indicate differential effects for boys and girls (data not 292 
shown). Birth weight and gestational age did not explain the effect of fish oil on the outcomes 293 
(supplementary Table V). 294 
  295 
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Table II. Characteristics of mother-child pairs in the Aarhus Trial  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Values are mean (SD), median (25th-75th %), or n (%). 
P-values calculated using Chi-square tests, t-tests, or Wilcoxon’s rank sum-tes
 Clinical examination  Questionnaire  
 Participants 
n=243 
Non-participants 
n=274 
p Participants 
n=382 
Non-participants 
n=135 
p 
Mother       
Randomization code   0.04   0.51 
     Fish oil 108 (44%) 152 (55%)  188 (49%) 72 (53%)  
     Olive oil 72 (30%) 62 (23%)  104 (27%) 30 (22%)  
     No oil 63 (26%) 60 (22%)  90 (24%) 33 (24%)  
Age (years) 29.8 (4.4) 28.9 (4.4) 0.03 29.7 (4.3) 28.5 (4.4) 0.01 
Parity (% nulliparous) 142 (58%) 160 (58%) 0.53 224 (59%) 78 (58%) 0.59 
Smoker (% non-smoker) 176 (72%) 180 (66%) 0.11 281 (74%) 75 (56%) <0.001 
Fish intake (% low intake) 46 (19%) 59 (22%) 0.76 76 (20%) 29 (21%) 0.22 
Pre-pregnancy BMI (kg/m2) 21.0 (19.7-22.7) 21.3 (20.1-23.2) 0.16 21.1 (19.8-22.7) 21.3 (20.0-24.0) 0.14 
Offspring       
Female (% girls) 136 (56%) 100 (37%) <0.001 194 (51%) 42 (31%) <0.001 
Birth weight (g) 3594.7 (458.8) 3485.4 (510.6) 0.01 3551.8 (500.2) 3494.3 (595.0) 0.25 
Gestational age (days) 283.0 (10.6) 281.4 (12.0) 0.10 282.3 (11.3) 281.6 (11.6) 0.54 
Asthma medication use 36 (14.8%) 35 (12.8%) 0.50 52 (13.6%) 19 (14.1%) 0.89 
Asthma discharge diagnosis 11 (4.5%) 13 (4.7%) 0.91 15 (3.9%) 9 (6.7%) 0.19 
Allergic rhinitis medication use 58 (23.4%) 65 (23.7%) 0.97 38 (28.2%) 85 (22.3%) 0.17 
14 
 
 
DISCUSSION 
Fewer children in the fish oil group compared to the olive oil group had been prescribed asthma 
medication during the 24-year follow-up period. This is in line with our earlier published 
observation14 that a smaller proportion of offspring in the fish oil group had been given a hospital 
asthma diagnosis. The main finding of the present study is that fish oil supplementation not only 
seems to have prophylactic potential on severe asthma, but also on mild to moderate asthma, which 
is a finding of high public health relevance. 
 
There are three possible explanations for our findings: 1) fish oil reduced the risk of asthma, 2) 
olive oil increased the risk of asthma), or 3) a combination of those two effects. We believe that the 
first explanation is most likely. The biological pathways underlying the positive impact of fish oil 
could be explained by a reduced TH2 immune response in the offspring exposed to n-3 
polyunsaturated fatty acids in fetal life. Fatty acids cross the placenta18 and EPA and DHA may 
directly affect the development of the fetal immune and respiratory systems by influencing cell 
signalling and gene expression; competing with arachidonic acid to produce less potent eicosanoids; 
and via the production of anti-inflammatory resolvins.19-21 Alternatively, fatty acids may act 
indirectly by skewing the maternal immune system towards a TH2 response, resulting in an 
increased production of inflammatory immune cells that cross the placenta and influence the fetal 
immune system development.22 Although olive oil provides linoleic acid, which through elongation 
and desaturation processes can form arachidonic acid, which in turn is a precursor for several 
inflammatory mediators, we do not believe that the given dosage of 4 g daily could result in any 
notable effects. In fact, the amount of olive oil in the placebo group provided <3% of average daily 
intake of linoleic acid at that time in Denmark.10 In contrast, the dosage of EPA and DHA of 2.7 g 
daily resulted in a ~10 fold increase in that nutrient. 
 
As shown in the supplementary material, offspring of mothers in the no oil group were remarkably 
similar to offspring in the fish oil group in terms of the occurrences of asthma and allergic disease. 
We believe this intriguing finding may be the result of contamination bias. All participants were 
informed about the study hypothesis relating 2.7 g n-3 PUFA supplementation in pregnancy with a 
reduced risk of preterm birth, and it is possible that those who subsequently did not receive any 
capsules as part of the trial have self-supplemented or increased their intake of fish during the study 
15 
 
period. Data collected post-partum asking about changes in fish intake and self-supplementation 
revealed such increases were indeed more frequent in the no oil group compared to the olive oil 
group. It can be argued that a passive intervention informing women about the potential beneficial 
effects of fish oil may be as effective as actual fish oil supplementation, at least in a group of 
motivated pregnant women.  
 
 
A major asset of the national prescription and patient registers is that they cover all citizens in 
Denmark. This becomes particularly potent in a randomised setting like ours. Since all individuals 
are followed, analyses could be performed as intention-to-treat and the full scientific advantage of 
the randomised design for making causal inferences retained, even in a long-term perspective. As a 
consequence of this, the observed differences in asthma occurrences across trial groups can with 
great certainty be ascribed to a causal effect of the fish oil compared to olive oil regimens.  
 
 
The two registers have their own characteristic patterns of misclassification. Milder asthma cases 
solely treated with asthma medicine prescribed by general practitioners or paediatricians but never 
admitted to hospital confers a higher sensitivity to the prescription register. This may however be at 
the cost of specificity, since asthma medication may be prescribed in order to clarify a suspected 
asthma diagnosis. We tried to avoid the latter problem by requiring at least two prescriptions for 
beta-2-agonists and steroids to be counted as a case based on medications. The fact that analyses 
based on the two different registers agreed in their conclusion, despite different underlying error 
sources, adds further credibility to the belief that the intervention group and placebo group truly did 
differ in asthma occurrences. Any misclassification with respect to identifying children who truly 
had or did not have asthma is likely to have occurred to a similar extent across the trial groups, and 
will have tended to attenuate our measures of association rather than create spurious ones. 
Additional support comes from the self-reported outcomes at 18-19 years of age. According to 
these, the odds of asthma tended to be lower in the fish oil compared the olive oil group, although 
the differences were significant only for current use of asthma medication.  
 
In contrast, no impact of fish oil was observed on the lung function measures. The clinical follow-
up of offspring required active participation, which implied a certain degree of differential attrition. 
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This could potentially have introduced biased estimates if non-participants had a different disease 
risk than participants, but there were no differences in disease occurrences according to register 
outcomes that were available for everyone in the cohort (Table II), making selection bias less likely 
to explain the results. The null results for lung function may rather be due to an influence of current 
asthma or hayfever medication use when assessing asthma at the clinical examination at age 18-19 
years. Although we asked offspring not to use any medication on the day of the examination, the 
use of long-acting medications especially inhaled corticosteroid in well-treated offspring may have 
prevented us from detecting any associations with the lung function outcomes. Furthermore, we 
observed no significant impact on parameters reflection sensitization such as total and specific IgE. 
Remarkably, the probability of being prescribed allergic rhinitis medication tended to be lower in 
the fish oil group compared to the olive oil group, and the effect of fish oil seemed to be strongest 
on the allergic asthma phenotype, which may still leave uncertainty about a role of allergic 
sensitization in mediating a possible protective effect of fish oil on asthma.  
 
 
Medication data regarding the first 5 years of follow-up in the prescription register were lacking, 
obstructing us from investigating common phenotypes of allergic disease in early childhood. In 
consequence, we are not able to compare our results to other RCTs in the field that have assessed 
allergic outcomes up to 3 years of age. These RCTs have, for the most part, shown favourable 
effects on immunological responses at birth3-5 and sensitization23;24 during the first 12 and 24 
months, respectively, but no effects on clinical outcomes such as eczema, food reactions, or 
wheezing and asthma. Perhaps this early effect on the immune response and sensitization may later 
establish itself clinically, as suggested by our results. Long-term follow-up of these RCTs will 
therefore be important.  
 
In conclusion, results from this randomised controlled trial showed that children whose mothers had 
taken fish oil in third trimester of pregnancy had a reduced probability of having had asthma 
medication prescribed and of receiving an asthma diagnosis during their childhood and early 
adulthood compared with children whose mothers had received olive oil. These results are 
compatible with the hypothesis that supplementation with n-3 PUFA late in pregnancy has 
prophylactic potential in preventing asthma in the offspring.  More generally, our results support the 
17 
 
hypothesis that the intrauterine environment is critical for the development of asthma, not only in 
childhood, but also in a long-term perspective. 
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Figure legends 
Figure 1. Participation flow in the Aarhus Trial 
Figure 2. 24-year follow-up of offspring from a randomized controlled trial (n=396) with fish oil 
supplementation in pregnancy. Kaplan-Meier survival curves show occurrences of asthma discharge 
diagnoses in the national patient register (2a), and asthma (2b) and allergic rhinitis medication use 
(2c), respectively, in the national prescription registry, stratified by randomization group. 
Figure 3. Odds ratios (ORs), ratios between geometric means, and mean differences with 95% 
confidence intervals of self-reported (3a) and clinical outcomes (3b and 3c) comparing offspring in 
the fish oil group to the olive oil group 
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Supplementary Table I. Hazard ratios (HRs) and 95% CIs of register outcomes of asthma and 
allergic rhinitis in the fish oil group and no oil group relative to the olive oil group. 
 
 
 
 
 
 
 
 
 
Hazard ratios calculated using Cox regression analysis. 
 
 
 
  
Registry-based outcomes (n=522) HR (95% CI) 
Asthma discharge diagnosis  
     Fish oil      0.31 (0.13-0.75) 
     No oil 0.24 (0.07-0.86) 
     Olive oil 1.00  
Asthma medication   
     Fish oil      0.54 (0.32-0.90) 
     No oil  0.43 (0.22-0.85) 
     Olive oil 1.00 
Allergic rhinitis medication   
     Fish oil      0.70 (0.47-1.05) 
     No oil 0.66 (0.40-1.08) 
     Olive oil 1.00 
23 
 
 
Supplementary Table II. Odds ratios (ORs) and 95% CIs of self-reported outcomes of asthma and 
hayfever in the fish oil group and no oil group relative to the olive oil group. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Odds ratios calculated using logistic regression. Adjusted for offspring sex and maternal smoking.  
Self-reported outcomes (n=382)              OR (95% CI) 
 Crude Adjusted 
Lifetime doctor diagnosis of asthma   
     Fish oil      0.52 (0.25-1.06) 0.50 (0.24-1.04) 
     No oil 0.44 (0.17-1.12) 0.41 (0.16-1.05) 
     Olive oil 1.00  1.00 
Current asthma medication use   
     Fish oil      0.35 (0.12-1.02) 0.34 (0.12-0.99) 
     No oil 0.37 (0.10-1.42) 0.34 (0.09-1.30) 
     Olive oil 1.00 1.00 
Lifetime doctor diagnosis of hayfever   
     Fish oil      0.64 (0.32-1.28) 0.64 (0.32-1.29) 
     No oil 1.00 (0.47-2.13) 1.00 (0.47-2.15) 
     Olive oil 1.00 1.00 
Current hayfever symptoms   
     Fish oil      0.72 (0.43-1.21) 0.70 (0.42-1.19) 
     No oil   0.96 (0.52-1.75) 0.92 (0.50-1.69) 
     Olive oil 1.00 1.00 
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Supplementary Table III. Odds ratios (ORs), mean differences (β), or ratios between geometric 
means in clinical outcomes of allergic sensitization, lung function, and ECP in the fish oil group and 
no oil group relative to the olive oil group. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Odds ratios calculated using logistic regression; β estimates and ratios between geometric means 
calculated using linear regression. Adjusted for offspring sex and maternal smoking. 
 
  
Outcomes from clinical examination (n=243) OR, β estimates*, or ratios between 
geometric means** (95% CI) 
 Crude Adjusted 
Specific IgE > 0.35 kUA/L   
     Fish oil      0.67 (0.36-1.25) 0.69 (0.37-1.28) 
     No oil 0.70 (0.35-1.41) 0.74 (0.36-1.50) 
     Olive oil 1.00 1.00 
FEV1/FVC (%)*   
     Fish oil      0.14 (-2.01, 2.28) -0.14 (-2.21, 1.92) 
     No oil 0.40 (-2.04, 2.83) 0.19 (-2.16, 2.54) 
     Olive oil 0.00 0.00 
FEV1% predicted (%)*   
     Fish oil      -1.40 (-4.57, 1.77) -1.33 (-4.51, 1.87) 
     No oil -2.06 (-5.66, 1.53) -1.90 (-5.54-1.74) 
     Olive oil 0.00 0.00 
Total IgE (kUA/L)**   
     Fish oil      1.13 (0.71, 1.80) 1.16 (0.73-1.86) 
     No oil 0.75 (0.45, 1.29) 0.80 (0.47-1.36) 
     Olive oil 1.00 1.00 
ECP (µg/L)**   
     Fish oil      1.04 (0.86, 1.27) 1.03 (0.85-1.26) 
     No oil 1.04 (0.85, 1.28) 1.00 (0.80-1.26) 
     Olive oil 1.00 1.00 
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Supplementary Table IV. Odds ratios (ORs), mean differences (β), or ratios between geometric 
means of self-reported and clinical outcomes of asthma, hay fever, allergic sensitization, lung 
function, total IgE, and ECP in the fish oil group relative to the olive oil group. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Odds ratios calculated using logistic regression; β estimates and ratios between geometric means 
calculated using linear regression. Adjusted for offspring sex and maternal smoking. 
  
Outcomes from clinical examination (n=180) OR, β estimates*, or ratios between 
geometric means** (95% CI) 
 Crude Adjusted 
Lifetime doctor diagnosis of asthma   
     Fish oil      0.52 (0.25-1.06) 0.50 (0.24-1.04) 
     Olive oil 1.00  1.00 
Current asthma medication use   
     Fish oil      0.35 (0.12-1.02) 0.34 (0.12-0.99) 
     Olive oil 1.00 1.00 
Lifetime doctor diagnosis of hayfever   
     Fish oil      0.64 (0.32-1.28) 0.64 (0.32-1.29) 
     Olive oil 1.00 1.00 
Current hayfever symptoms   
     Fish oil      0.72 (0.43-1.21) 0.70 (0.42-1.19) 
     Olive oil 1.00 1.00 
Total IgE (kUA/L)**   
     Fish oil      1.13 (0.72, 1.77) 1.16 (0.75-1.83) 
     Olive oil 1.00 1.00 
ECP (µg/L)**   
     Fish oil      1.04 (0.86, 1.27) 1.03 (0.85-1.26) 
     Olive oil 1.00 1.00 
Specific IgE > 0.35 kUA/L   
     Fish oil      0.67 (0.36-1.25) 0.69 (0.37-1.28) 
     Olive oil 1.00 1.00 
FEV1/FVC (%)*   
     Fish oil      0.14 (-1.82, 2.10) -0.04 (-1.96, 1.89) 
     Olive oil 0.00 0.00 
FEV1% predicted (%)*   
     Fish oil      -1.40 (-4.60, 1.81) -1.21 (-4.43, 2.01) 
     Olive oil 0.00 0.00 
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Supplementary Table V. Hazard ratios (HRs) and 95% CIs of register outcomes of asthma and 
allergic rhinitis in the fish oil group relative to the olive oil group adjusted for birth weight and 
gestational age. 
 
 
 
 
Hazard ratios calculated using Cox regression. 
 
 
 
 
 
 
 
 
 
 
 
 
 Crude Adjustment for birth weight Adjustment for gestational age 
Registry-based outcomes 
(n=394) 
HR (95% CI) HR (95% CI) HR (95% CI) 
 Asthma discharge diagnosis    
     Fish oil      0.31 (0.13-0.75) 0.33 (0.14-0.81) 0.31 (0.13-0.76) 
     Olive oil 1.00  1.00  1.00  
Asthma medication     
     Fish oil      0.54 (0.32-0.90) 0.56 (0.33-0.94) 0.55 (0.33-0.93) 
     Olive oil 1.00 1.00 1.00 
Allergic rhinitis medication     
     Fish oil      0.70 (0.47-1.05) 0.69 (0.46-1.04) 0.70 (0.47-1.06) 
     Olive oil 1.00 1.00 1.00 
